Thelansis’s “Global Lyme Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lyme Disease treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Lyme disease, caused by Borrelia burgdorferi and transmitted through Ixodes tick bites, is the most prevalent vector-borne illness across North America and Europe, with its incidence climbing due to climate-driven tick range expansion. Diagnosis relies on clinical presentation and two-tier serology. Early-stage infection is typically curable with doxycycline or amoxicillin, but delayed treatment can progress to debilitating neurological, cardiac, and arthritic complications, while post-treatment Lyme disease syndrome remains poorly understood. Prophylactic options have advanced significantly with Pfizer and Valneva’s investigational 6-valent OspA-based vaccine candidate PF-07307405. In the Phase 3 VALOR trial results announced in March 2026, the vaccine demonstrated 73.2 to 74.8 percent efficacy in preventing confirmed cases. Crucially, due to a lower-than-expected number of infections during the study period, the trial technically missed its strict primary statistical endpoint in the first analysis, though a secondary pre-specified analysis confirmed clinically meaningful protection. Based on these data, regulatory submissions to the FDA and EMA are moving forward this year. If approved, it will become the first human Lyme disease vaccine available since the withdrawal of LYMErix in 2002, filling a massive public health gap.
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Global Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report
Our team will get in touch with you shortly about the Global Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report.